Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaxCyte Share News (MXCT)

Share Price Information for MaxCyte (MXCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 380.00
Bid: 374.00
Ask: 386.00
Change: 0.00 (0.00%)
Spread: 12.00 (3.209%)
Open: 380.00
High: 380.00
Low: 380.00
Prev. Close: 380.00
MXCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MaxCyte expecting strong 2023 after decent results

Thu, 16th Mar 2023 15:01

(Sharecast News) - Cell engineering specialist MaxCyte reported total revenue of $12.4m in the fourth quarter of 2022 on Thursday, making for an increase of 22% year-on-year.

The AIM-traded company said full-year revenue for 2022 was $44.3m, representing growth of 31% compared to 2021.

It said its core business revenue increased 4% in the fourth quarter, led by a 4% increase in revenue from cell therapy customers and a 5% increase in revenue from drug discovery clients.

For the full year, core business revenues grew 26%, with cell therapy revenue up 33% and drug discovery revenue ahead 8%.

Looking ahead, MaxCyte said it was expecting total revenue growth of 21% to 26% over 2022 this year, including core revenue growth of 20% to 25%.

Additionally, it said it expected strategic platform licence (SPL) programme-related revenue of about $6m.

The firm reported total cash, cash equivalents, and short-term investments of $227.3m at year-end on 31 December.

"We are pleased with our strong progress and performance in 2022 and look forward to continuing this positive momentum into 2023," said president and chief executive officer Doug Doerfler.

"Over the course of the year, we have made significant investments in our people, manufacturing capacity, and research and development infrastructure, which positions us well for our next stage of growth.

"Our portfolio of partnerships continued to grow throughout 2022, having announced three new SPL partnerships as well as the recent addition of Catamaran Bio as a partner in early 2023."

Doerfler noted that MaxCyte also entered into a partnership with Vertex following the transfer of the exa-cel program from CRISPR.

"The partnership maintains our role in this program, for which Vertex is currently seeking regulatory marketing approval in the United States and Europe for sickle cell disease and beta-thalassemia.

"We are continuing to see our partners make strong progress across their clinical programs and are focused on providing them with the in-house manufacturing and regulatory support that they will require as they move towards commercialization.

"Our partnership pipeline remains robust and growing as we begin 2023 and we are excited to see our partners achieve upcoming milestones and move the cell therapy industry forward."

At 1442 GMT, shares in MaxCyte were flat at 1442 GMT.

Reporting by Josh White for Sharecast.com.

More News
3 Feb 2021 21:38

IN BRIEF: GBP40 Million MaxCyte Subscription Ahead Of Dual Listing

IN BRIEF: GBP40 Million MaxCyte Subscription Ahead Of Dual Listing

Read more
20 Jan 2021 17:40

LONDON TRADING UPDATES: Alliance Pharma 2020 Revenue Slips By 5%

LONDON TRADING UPDATES: Alliance Pharma 2020 Revenue Slips By 5%

Read more
11 Jan 2021 14:51

UK TRADING UPDATE SUMMARY: Science Group To Beat Forecasts For 2020

UK TRADING UPDATE SUMMARY: Science Group To Beat Forecasts For 2020

Read more
23 Dec 2020 10:36

Maxcyte Core Life Sciences Business Results To Beat Expectations

Maxcyte Core Life Sciences Business Results To Beat Expectations

Read more
23 Oct 2020 16:04

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
13 Oct 2020 14:06

UK EXECUTIVE CHANGE SUMMARY: Danakali Hires Potash Mining Vet As COO

UK EXECUTIVE CHANGE SUMMARY: Danakali Hires Potash Mining Vet As COO

Read more
21 Sep 2020 16:24

IN BRIEF: MaxCyte Interim Revenue Jumps And Loss Narrows

IN BRIEF: MaxCyte Interim Revenue Jumps And Loss Narrows

Read more
14 Sep 2020 15:44

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
9 Sep 2020 14:28

MaxCyte Hires Murphy As Finance Chief; Holtz Becomes Accounting Boss

MaxCyte Hires Murphy As Finance Chief; Holtz Becomes Accounting Boss

Read more
9 Sep 2020 09:35

MaxCyte appoints Amanda Murphy as CFO

(Sharecast News) - Life sciences company MaxCyte named Amanda Murphy as its chief financial officer on Wednesday, succeeding long-time CFO Ron Holtz.

Read more
18 Aug 2020 20:04

IN BRIEF: MaxCyte Says CARMA's Phase 1 MCY-M11 Trial Expanded

IN BRIEF: MaxCyte Says CARMA's Phase 1 MCY-M11 Trial Expanded

Read more
15 Jul 2020 13:31

MaxCyte Sees Higher Interim Revenue, Confident On Long-Term Prospects

MaxCyte Sees Higher Interim Revenue, Confident On Long-Term Prospects

Read more
8 Jul 2020 15:51

IN BRIEF: MaxCyte Signs APN401 Licensing Deal With Apeiron Biologics

IN BRIEF: MaxCyte Signs APN401 Licensing Deal With Apeiron Biologics

Read more
7 May 2020 17:30

UK TRADING UPDATE SUMMARY: Filta Launches Covid-19 Sanitising Service

UK TRADING UPDATE SUMMARY: Filta Launches Covid-19 Sanitising Service

Read more
1 May 2020 08:54

MaxCyte Raises GBP25 Million To Fund Investments Ahead Of US IPO

MaxCyte Raises GBP25 Million To Fund Investments Ahead Of US IPO

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.